Developer docs
API playgroundTry for free, no card

Search company profiles

The Column Group

Full company profile

uuid00004h5

Namestring
The Column Group
Legal namestring
The Column Group, LLC
Company typeenum
Private
Founded yearint
2007
Descriptiontext

The Column Group (TCG) is a private venture capital firm founded in 2007 by Peter Svennilson in San Francisco, California, dedicated exclusively to building biotechnology companies from inception through exit. TCG operates an "edge-to-edge" investment model deploying capital across four coordinated vehicles: TCG Platform funds (early-stage company formation, making 3-4 investments per year and averaging 10-12 portfolio companies per fund at $50-60 million+ per company), TCG Opportunity funds (later-stage follow-on to concentrate ownership in TCG portfolio companies), TCG Labs-Soleil (a February 2024-launched venture-biotech model integrating a $400 million+ venture fund with an evergreen R&D hub for single-asset biologic therapies), and TCG Crossover/TCGX (a 2021-launched crossover fund for late-stage and public drug-discovery investments that is operationally independent of TCG core).

Over a two-decade history, TCG has started or invested in 55 companies and generated $4.0 billion in returns for partners and portfolio across 18 exits. Notable exits include Carmot Therapeutics (Roche, $3.3B, December 2023), RAPT Therapeutics (GSK, $2.2B, January 2026), Peloton Therapeutics (Merck, up to $2.35B, May 2019), Constellation Pharmaceuticals (MorphoSys, $1.7B, June 2021), Flexus Biosciences (BMS, $1.3B, April 2015), Neurona Therapeutics (UCB, up to $1.15B, April 2026), and Escient Pharmaceuticals (Incyte, $783M, April 2024). Fund family includes TCG IV at $725 million, TCG V at $615 million plus TCG Opportunity III at $615 million ($1.23 billion total), and TCG Labs-Soleil at over $400 million. Revenue is generated through management fees and carried interest on its fund family alongside capital gains from portfolio exits.

TCG's competitive position rests on a deep scientific talent ecosystem — 22 elite academic advisors, 10 National Academy of Sciences members, and one Nobel Prize winner (Jennifer Doudna) serve as iPartners and Science Partners to source, validate, and mentor portfolio ventures. The portfolio spans modalities including small molecules (Atavistik Bio allosteric inhibitors, Nura Bio SARM1 inhibitors, ORIC Pharmaceuticals), engineered cytokines and large molecules (Synthekine, Kallyope), cell therapies (Neurona, Tr1X, A2 Biotherapeutics), gene therapy (Tenaya Therapeutics), and regenerative medicine (Surrozen). TCG also operates the Swanson Fellowship Program (named for Genentech co-founder Robert Swanson) and a centralized portfolio job board as part of its talent and company-formation infrastructure.

Short descriptiontext

The Column Group is a private venture capital firm founded in 2007 that builds biotechnology companies from inception through exit. It deploys capital across TCG Platform, Opportunity, Labs-Soleil, and TCGX funds, with $4.0 billion in returns generated across 18 exits and 55 portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funds, biotech investments, life sciences venture, company formation, venture biotech funding
Industry2 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAGAH
Thematic / Sector-Focused Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital (Biotechnology)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Venture capital fund management and carried interest
TypeManaged Services
Description

TCG generates revenue through management fees and carried interest on its venture capital funds — TCG Platform funds (V at $615M early-stage plus Opportunity III at $615M later-stage, total $1.23B), TCG IV ($725M), and TCG Labs-Soleil (over $400M). TCG reports $4.0 billion in returns generated for partners and portfolio across 18 exits.

thecolumngroup.com
2Capital gains from portfolio exits and IPOs
TypeTransaction Fee
Description

Returns generated through successful portfolio exits (18 to date) and public holdings in companies including Revolution Medicines (RVMD), ORIC Pharmaceuticals (ORIC), Tenaya Therapeutics (TNYA), Arcus Biosciences (RCUS), Nurix (NRIX), Gritstone Bio (GRTS), and RAPT Therapeutics (RAPT). Notable exits include Carmot (Roche, $3.3B), Peloton (Merck, up to $2.35B), Aragon (J&J, up to $1B), Seragon (Genentech, $0.8B), Neurona (UCB, up to $1.15B), Constellation (MorphoSys, $1.7B), Exonics (Vertex, up to $1B), Flexus (BMS, $1.3B), RAPT (GSK, $2.2B), Escient (Incyte, $783M), and Immune Design (Merck, $0.3B).

thecolumngroup.com
3Crossover fund investments (TCGX)
TypeLicensing Royalties
Description

TCG Crossover (TCGX), launched in 2021 and operationally independent of TCG, invests in later-stage pre-IPO and public drug discovery companies.

thecolumngroup.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Fund commitment-based capital allocation (limited partners commit capital to TCG funds)
ModelOther
Notes

TCG V ($615M) and TCG Opportunity III ($615M) closed together at $1.23B; TCG IV raised $725M; TCG Labs-Soleil raised over $400M; typical initial investment of $50–60M+ per portfolio company.

thecolumngroup.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1TCG Labs-Soleil
Description

A novel venture-biotech model integrating a dedicated venture fund (TCG Labs, over $400 million) with an evergreen R&D hub (Soleil), focused on single-asset biologic therapies for serious diseases.

thecolumngroup.com
+1 more record
Core offering1 text field

The Column Group is a private venture capital firm dedicated to founding, funding, and growing biotechnology companies across small molecules, biologics, cell therapy, gene therapy, and regenerative medicine. It deploys capital through a coordinated family of funds — TCG Platform, TCG Opportunity, TCG Labs-Soleil, and TCG Crossover (TCGX) — that together support portfolio companies from inception through exit, supplemented by the Swanson Fellowship Program and a deep scientific advisor network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • $4.0 billion in returns generated for partners and portfolio
+8 more records
Product overview1 text field

The Column Group (TCG) is a venture capital firm and life sciences investment platform, not a single software product. Its offering is structured as a platform-plus-modules ecosystem comprising multiple investment vehicles and programs: (1) TCG Platform Funds, the legacy early-stage investment model focused on company formation with 3-4 investments per year; (2) TCG Opportunity Funds, follow-on capital supporting TCG portfolio companies through later stages; (3) TCG Labs-Soleil, a 2024-launched venture-biotech model combining a $400M fund (TCG Labs) with an evergreen R&D hub (Soleil) focused on single-asset biologic therapies; and (4) TCG Crossover (TCGX), the ecosystem's first crossover fund for late-stage pre-IPO and public drug discovery companies (operationally independent). Beyond capital deployment, TCG operates the Swanson Fellowship Program, a one-year biotech leadership fellowship for new company creation, and an iPartners advisory group of leading academic investigators. These vehicles collectively fund and nurture a portfolio of 55+ biotech companies that have generated $4.0 billion in returns and 18 exits, with active companies spanning modalities from small molecules (e.g., Nura Bio, Atavistik Bio, ORIC Pharmaceuticals) and large molecules (e.g., Synthekine cytokines, Kallyope gut-brain axis therapeutics) to cell therapies (e.g., Neurona Therapeutics, Tr1x Bio, A2 Biotherapeutics), gene therapy (e.g., Tenaya Therapeutics), and oligonucleotides (e.g., Judo Bio).

Product and service5 records
1TCG Platform Funds
CategoryInvestment Fund Family
Description

Early-stage venture capital funds that partner with scientific founders to build biotech companies from inception through exit, selectively investing in 3-4 highly vetted ideas per year and averaging 10-12 portfolio companies per fund with $50-60M+ typically invested in each company.

2TCG Opportunity Funds
CategoryInvestment Fund Family
Description

Follow-on venture capital funds that build on TCG Platform fund momentum by providing a flexible pool of capital to support TCG's most promising companies through later stages of development and concentrate ownership within the TCG portfolio.

3TCG Labs-Soleil
CategoryVenture-Biotech Fund + R&D Hub
Description

A pioneering venture-biotech model launched in February 2024 that integrates a dedicated venture fund of over $400 million (TCG Labs) with an evergreen R&D hub led by top-tier scientists and drug developers (Soleil), focused on single-asset programs for efficient discovery and development of biologic-based therapies for serious diseases.

4TCG Crossover (TCGX)
CategoryCrossover Investment Fund
Description

The first crossover fund debuted under the TCG ecosystem in 2021, dedicated to investing in later-stage pre-IPO and publicly-traded drug discovery companies, with the goal of supporting the translation of cutting-edge science into products that make a meaningful difference for patients.

5Swanson Fellowship Program
CategoryBiotech Leadership Fellowship
Description

A one-year fellowship opportunity for aspiring biotech leaders, named in honor of Robert Swanson (co-founder of Genentech), focused on new company creation with hands-on mentorship from the TCG team and its iPartners in a collaborative working environment.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership19 partners
Strategic tierCore Portfolio Company — Led $73.8M Series B.TypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Nura Bio completed a $73.8M Series B led by The Column Group with participation from Samsara BioCapital, Euclidean Capital, and Sanofi Ventures. The funding advances Nura's SARM1 inhibitor pipeline, including a Phase 1b/2a study of NB-4746 for ALS and a first-in-human study of NB-9402, a next-generation covalent allosteric SARM1 inhibitor. Tim Kutzkey, PhD serves on the board; John Josey, PhD is Chairman of Atavistik Bio and involved with Nura Bio board.

Strategic tierCore Portfolio Company — Co-Led $106M Seed And Series A.TypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Tortugas Neuroscience launched in Framingham, Massachusetts with $106M in combined seed and Series A financing co-led by Cure Ventures, The Column Group, and AN Venture Partners. Funding supports Phase 2 clinical trials for two lead CNS candidates targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. Programs were in-licensed from Eisai Co., Ltd. (Japan) and Jiangsu Hansoh Pharmaceutical Group (China). Led by former Sage Therapeutics executives Jeff Jonas (CEO) and Al Robichaud (R&D head).

Strategic tierMajor Acquirer — Acquired Neurona Therapeutics For Up To $1.15B In April 2026.TypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

UCB acquired Neurona Therapeutics (a TCG portfolio company developing cell therapies for neuropsychiatric disorders including epilepsy) in April 2026 for up to $1.15 billion, advancing UCB's leadership in epilepsy through regenerative science.

4Eisai Co., Ltd.
Strategic tierStrategic Partner — Tortugas Neuroscience In-Licensed Clinical-Stage Cns Programs From Eisai.TypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Eisai Co., Ltd. (Japan) licensed clinical-stage CNS drug candidates to Tortugas Neuroscience (TCG portfolio company), targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies.

biospace.com
5Jiangsu Hansoh Pharmaceutical Group
Strategic tierStrategic Partner — Tortugas Neuroscience In-Licensed Clinical-Stage Cns Programs From Hansoh.TypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Jiangsu Hansoh Pharmaceutical Group (China) licensed clinical-stage CNS drug candidates to Tortugas Neuroscience (TCG portfolio company).

biospace.com
Strategic tierMajor Acquirer — Acquired Rapt Therapeutics For $2.2B In January 2026.TypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

GSK acquired RAPT Therapeutics (NASDAQ: RAPT), a TCG portfolio company developing oral therapeutics targeting immune drivers of cancer and inflammation, in January 2026 for $2.2 billion.

Strategic tierCore Portfolio Company — Co-Led Series B.TypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Atavistik Bio raised $120M Series B (later extended to $160M total) led by Nextech Invest and The Column Group, with participation from Lux Capital and Regeneron Ventures. The funding advances an oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs). HHT program expected to enter the clinic in H1 2026. Also disclosed a research collaboration with Pfizer to accelerate discovery of novel precision allosteric therapeutics.

Strategic tierCore Portfolio Company — Led Series A Financing.TypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Nilo Therapeutics launched with a $101M Series A led by The Column Group, DCVC Bio, and Lux Capital, with support from the Gates Foundation and Alexandria Venture Investments. The funding supports labs in New York City, R&D expansion, and preclinical programs targeting neural circuits to restore immune homeostasis in autoimmune and inflammatory diseases. Kim Seth was appointed CEO.

9Swanson Fellowship Program / Robert Swanson legacy
Strategic tierFlagship Talent And Ideation Program — Named After Genentech Co-Founder Robert Swanson.TypeOthersAnnounced on2025-01-01
Description

The Swanson Fellowship program is a one-year fellowship opportunity for aspiring biotech leaders, focused on new company creation with hands-on mentorship from the TCG team and its iPartners. Named in honor of Robert Swanson, the Co-Founder of Genentech, often considered the father of the biotechnology industry.

thecolumngroup.com
Strategic tierMajor Acquirer — Acquired Escient Pharmaceuticals For $783M In April 2024.TypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Incyte acquired Escient Pharmaceuticals (TCG portfolio company advancing first-in-class GPCR-targeted drugs) in April 2024 for $783 million.

Strategic tierFlagship Internal Program — $400M+ Venture-Biotech Fund Integrated With R&D Hub.TypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

TCG Labs-Soleil, launched in February 2024 with over $400M, represents a pioneering venture-biotech model integrating a dedicated venture fund (TCG Labs) with an evergreen R&D hub (Soleil) led by top-tier scientists. Focused on single-asset programs for efficient discovery and development of biologic-based therapies.

Strategic tierStrategic Research Collaboration Partner With Tcg Portfolio Company Atavistik Bio.TypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Pfizer entered a research collaboration with Atavistik Bio (TCG portfolio company) to accelerate discovery of novel precision allosteric therapeutics for metabolite-protein interactions in metabolic diseases and cancer.

Strategic tierMajor Acquirer — Acquired Tcg Portfolio Company Carmot Therapeutics For $3.3B In December 2023.TypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Roche acquired Carmot Therapeutics (a TCG portfolio company using Chemotype Evolution drug discovery) in December 2023 for $3.3 billion. Separately, Genentech/Roche acquired TCG portfolio company Seragon Pharmaceuticals in August 2014 for $0.8 billion.

Strategic tierMajor Acquirer — Acquired Constellation Pharmaceuticals For $1.7B In June 2021.TypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

MorphoSys acquired Constellation Pharmaceuticals (TCG portfolio company pioneering therapeutics targeting epigenetic regulators) on June 2, 2021 for $1.7 billion.

Strategic tierFlagship Internal Program — First Crossover Fund In Tcg Ecosystem.TypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

TCG Crossover (TCGX), launched in 2021, is the first crossover fund debuted under the TCG ecosystem, dedicated to investing in later-stage pre-IPO and public drug discovery companies. Operationally independent of The Column Group (TCG).

Strategic tierMajor Acquirer — Acquired Exonics Therapeutics For Up To $1B In June 2019.TypeStrategic or Co-development PartnerAnnounced on2019-06-01
Description

Vertex Pharmaceuticals acquired Exonics Therapeutics (TCG portfolio company developing CRISPR/Cas9 gene editing medicines for Duchenne muscular dystrophy) on June 6, 2019 for up to $1 billion.

Strategic tierMajor Acquirer — Acquired Peloton Therapeutics For Up To $2.35B In May 2019; Also Acquired Immune Design For $0.3B In February 2019.TypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

Merck acquired TCG portfolio company Peloton Therapeutics (first-in-class small-molecule oncology pipeline) in May 2019 for up to $2.35 billion. Merck also previously acquired TCG portfolio company Immune Design (immunotherapy oncology) in February 2019 for $0.3 billion.

18Bristol-Myers Squibb
Strategic tierMajor Acquirer — Acquired Flexus Biosciences For $1.3B In April 2015.TypeStrategic or Co-development PartnerAnnounced on2015-04-01
Description

Bristol-Myers Squibb acquired Flexus Biosciences (TCG portfolio company creating cancer therapeutics through immunology insights) in April 2015 for $1.3 billion.

thecolumngroup.com
Strategic tierMajor Acquirer — Acquired Aragon Pharmaceuticals For Up To $1B In August 2013.TypeStrategic or Co-development PartnerAnnounced on2013-08-01
Description

Johnson & Johnson acquired TCG portfolio company Aragon Pharmaceuticals (nuclear receptor targeting drugs for hormone resistant cancers) in August 2013 for up to $1 billion.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arch Venture Partners is a leading biotech-focused venture capital firm that co-invests and competes with TCG for early-stage life sciences opportunities, particularly at company formation. Both firms back scientific founders at top universities and have produced multiple pharma exits (Arch: Illumina, Receptos, Vir).

TypeDirect peer
Description

Flagship Pioneering is a biotech creation engine that both internally generates companies (like Moderna) and partners with academic founders. Highly comparable to TCG's company-formation-led model and its recent TCG Labs-Soleil venture-biotech hybrid approach.

TypeDirect peer
Description

Third Rock Ventures builds biotech companies from academic science with a hands-on operating partner model — directly parallel to TCG's company formation approach. Both firms concentrate on early-stage therapeutic platforms with strong scientific founders.

TypeDirect peer
Description

Atlas Venture is an early-stage biotech venture firm that builds companies from scratch around academic science — a closely comparable model to TCG Platform funds. Both firms back founders across modalities with focused portfolios.

TypeDirect peer
Description

Versant Ventures is a healthcare-focused venture firm with comparable company-creation capabilities (e.g., Inception Sciences). Direct competitor for early-stage biotech deals and a natural co-investor or alternative for biotech founders.

TypeDirect peer
Description

5AM Ventures is an early-stage biotech venture firm founded by former TCG-affiliated scientists and focused on company formation. It competes with TCG for academic founders and platform technologies in therapeutics.

TypeDirect peer
Description

OrbiMed is one of the largest dedicated healthcare venture firms investing across stages. It is comparable in biotech focus, multi-stage capital deployment, and is a frequent competitor/co-investor of TCG (Leon Chen previously at OrbiMed).

TypeBroad incumbent
Description

a16z's bio/health fund is a broader, larger tech-oriented investor that has expanded into life sciences. It competes for biotech founders and capital but operates a multi-vertical model with technology as its core, unlike TCG's pure-play biotech focus.

TypeBroad incumbent
Description

RA Capital is a healthcare-focused crossover and public-market investor (co-invested in Atavistik Bio's Series B extension). Comparable in biotech life-sciences focus but operates a broader crossover/public equity model in addition to private venture.

10Baker Bros. Advisors
TypeBroad incumbent
Description

Baker Bros. is a long-only biotech-focused investment firm with significant public and private healthcare exposure. Comparable as a high-conviction biotech specialist and competitor for both private rounds and public crossover deals alongside TCGX.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers28 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment140 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Column Group

Venture Capital (Biotechnology)thecolumngroup.com

The Column Group is a private venture capital firm founded in 2007 that builds biotechnology companies from inception through exit. It deploys capital across TCG Platform, Opportunity, Labs-Soleil, and TCGX funds, with $4.0 billion in returns generated across 18 exits and 55 portfolio companies.

What The Column Group does

The Column Group (TCG) is a private venture capital firm founded in 2007 by Peter Svennilson in San Francisco, California, dedicated exclusively to building biotechnology companies from inception through exit. TCG operates an "edge-to-edge" investment model deploying capital across four coordinated vehicles: TCG Platform funds (early-stage company formation, making 3-4 investments per year and averaging 10-12 portfolio companies per fund at $50-60 million+ per company), TCG Opportunity funds (later-stage follow-on to concentrate ownership in TCG portfolio companies), TCG Labs-Soleil (a February 2024-launched venture-biotech model integrating a $400 million+ venture fund with an evergreen R&D hub for single-asset biologic therapies), and TCG Crossover/TCGX (a 2021-launched crossover fund for late-stage and public drug-discovery investments that is operationally independent of TCG core).

Over a two-decade history, TCG has started or invested in 55 companies and generated $4.0 billion in returns for partners and portfolio across 18 exits. Notable exits include Carmot Therapeutics (Roche, $3.3B, December 2023), RAPT Therapeutics (GSK, $2.2B, January 2026), Peloton Therapeutics (Merck, up to $2.35B, May 2019), Constellation Pharmaceuticals (MorphoSys, $1.7B, June 2021), Flexus Biosciences (BMS, $1.3B, April 2015), Neurona Therapeutics (UCB, up to $1.15B, April 2026), and Escient Pharmaceuticals (Incyte, $783M, April 2024). Fund family includes TCG IV at $725 million, TCG V at $615 million plus TCG Opportunity III at $615 million ($1.23 billion total), and TCG Labs-Soleil at over $400 million. Revenue is generated through management fees and carried interest on its fund family alongside capital gains from portfolio exits.

TCG's competitive position rests on a deep scientific talent ecosystem — 22 elite academic advisors, 10 National Academy of Sciences members, and one Nobel Prize winner (Jennifer Doudna) serve as iPartners and Science Partners to source, validate, and mentor portfolio ventures. The portfolio spans modalities including small molecules (Atavistik Bio allosteric inhibitors, Nura Bio SARM1 inhibitors, ORIC Pharmaceuticals), engineered cytokines and large molecules (Synthekine, Kallyope), cell therapies (Neurona, Tr1X, A2 Biotherapeutics), gene therapy (Tenaya Therapeutics), and regenerative medicine (Surrozen). TCG also operates the Swanson Fellowship Program (named for Genentech co-founder Robert Swanson) and a centralized portfolio job board as part of its talent and company-formation infrastructure.

The Column Group firmographics

Firmographics
Name
The Column Group
Legal name
The Column Group, LLC
Website
https://thecolumngroup.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
The Column Group is a private venture capital firm founded in 2007 that builds biotechnology companies from inception through exit. It deploys capital across TCG Platform, Opportunity, Labs-Soleil, and TCGX funds, with $4.0 billion in returns generated across 18 exits and 55 portfolio companies.
Ownership category
akta.pro rank

The Column Group industry classification

Industry
Product category
Venture Capital (Biotechnology)
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAGAH
Thematic / Sector-Focused Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital funds
  • Biotech investments
  • Life sciences venture
  • Company formation
  • Venture biotech funding

Where The Column Group is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

The Column Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Venture capital fund management and carried interest: TCG generates revenue through management fees and carried interest on its venture capital funds — TCG Platform funds (V at $615M early-stage plus Opportunity III at $615M later-stage, total $1.23B), TCG IV ($725M), and TCG Labs-Soleil (over $400M). TCG reports $4.0 billion in returns generated for partners and portfolio across 18 exits.
  2. Capital gains from portfolio exits and IPOs: Returns generated through successful portfolio exits (18 to date) and public holdings in companies including Revolution Medicines (RVMD), ORIC Pharmaceuticals (ORIC), Tenaya Therapeutics (TNYA), Arcus Biosciences (RCUS), Nurix (NRIX), Gritstone Bio (GRTS), and RAPT Therapeutics (RAPT). Notable exits include Carmot (Roche, $3.3B), Peloton (Merck, up to $2.35B), Aragon (J&J, up to $1B), Seragon (Genentech, $0.8B), Neurona (UCB, up to $1.15B), Constellation (MorphoSys, $1.7B), Exonics (Vertex, up to $1B), Flexus (BMS, $1.3B), RAPT (GSK, $2.2B), Escient (Incyte, $783M), and Immune Design (Merck, $0.3B).
  3. Crossover fund investments (TCGX): TCG Crossover (TCGX), launched in 2021 and operationally independent of TCG, invests in later-stage pre-IPO and public drug discovery companies.

Pricing tiers

ModelBillingPrice
Other—Fund commitment-based capital allocation (limited partners commit capital to TCG funds)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

The Column Group product offering

Product offering

Core offering

The Column Group is a private venture capital firm dedicated to founding, funding, and growing biotechnology companies across small molecules, biologics, cell therapy, gene therapy, and regenerative medicine. It deploys capital through a coordinated family of funds — TCG Platform, TCG Opportunity, TCG Labs-Soleil, and TCG Crossover (TCGX) — that together support portfolio companies from inception through exit, supplemented by the Swanson Fellowship Program and a deep scientific advisor network.

Product overview

The Column Group (TCG) is a venture capital firm and life sciences investment platform, not a single software product. Its offering is structured as a platform-plus-modules ecosystem comprising multiple investment vehicles and programs: (1) TCG Platform Funds, the legacy early-stage investment model focused on company formation with 3-4 investments per year; (2) TCG Opportunity Funds, follow-on capital supporting TCG portfolio companies through later stages; (3) TCG Labs-Soleil, a 2024-launched venture-biotech model combining a $400M fund (TCG Labs) with an evergreen R&D hub (Soleil) focused on single-asset biologic therapies; and (4) TCG Crossover (TCGX), the ecosystem's first crossover fund for late-stage pre-IPO and public drug discovery companies (operationally independent). Beyond capital deployment, TCG operates the Swanson Fellowship Program, a one-year biotech leadership fellowship for new company creation, and an iPartners advisory group of leading academic investigators. These vehicles collectively fund and nurture a portfolio of 55+ biotech companies that have generated $4.0 billion in returns and 18 exits, with active companies spanning modalities from small molecules (e.g., Nura Bio, Atavistik Bio, ORIC Pharmaceuticals) and large molecules (e.g., Synthekine cytokines, Kallyope gut-brain axis therapeutics) to cell therapies (e.g., Neurona Therapeutics, Tr1x Bio, A2 Biotherapeutics), gene therapy (e.g., Tenaya Therapeutics), and oligonucleotides (e.g., Judo Bio).

Differentiator

Problem solved

Functional benefit

Brands

  • TCG Labs-Soleil: A novel venture-biotech model integrating a dedicated venture fund (TCG Labs, over $400 million) with an evergreen R&D hub (Soleil), focused on single-asset biologic therapies for serious diseases.
  • TCG Crossover (TCGX)

Products and services

  • TCG Platform Funds Early-stage venture capital funds that partner with scientific founders to build biotech companies from inception through exit, selectively investing in 3-4 highly vetted ideas per year and averaging 10-12 portfolio companies per fund with $50-60M+ typically invested in each company.
  • TCG Opportunity Funds Follow-on venture capital funds that build on TCG Platform fund momentum by providing a flexible pool of capital to support TCG's most promising companies through later stages of development and concentrate ownership within the TCG portfolio.
  • TCG Labs-Soleil A pioneering venture-biotech model launched in February 2024 that integrates a dedicated venture fund of over $400 million (TCG Labs) with an evergreen R&D hub led by top-tier scientists and drug developers (Soleil), focused on single-asset programs for efficient discovery and development of biologic-based therapies for serious diseases.
  • TCG Crossover (TCGX) The first crossover fund debuted under the TCG ecosystem in 2021, dedicated to investing in later-stage pre-IPO and publicly-traded drug discovery companies, with the goal of supporting the translation of cutting-edge science into products that make a meaningful difference for patients.
  • Swanson Fellowship Program A one-year fellowship opportunity for aspiring biotech leaders, named in honor of Robert Swanson (co-founder of Genentech), focused on new company creation with hands-on mentorship from the TCG team and its iPartners in a collaborative working environment.

Quantifiable outcome

  • $4.0 billion in returns generated for partners and portfolio
  • +8 more outcomes

Companies that use The Column Group

Customer profile

Named customers28 records

Segments5 records

Ideal customer profiles3 records

The Column Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

The Column Group partnerships and signals

Strategic signal

Partnerships

19 partnerships are on record, tiered core portfolio company — led $73.8m series b., core portfolio company — co-led $106m seed and series a., major acquirer — acquired neurona therapeutics for up to $1.15b in april 2026., strategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from eisai., strategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from hansoh., major acquirer — acquired rapt therapeutics for $2.2b in january 2026., core portfolio company — co-led series b., core portfolio company — led series a financing., flagship talent and ideation program — named after genentech co-founder robert swanson., major acquirer — acquired escient pharmaceuticals for $783m in april 2024., flagship internal program — $400m+ venture-biotech fund integrated with r&d hub., strategic research collaboration partner with tcg portfolio company atavistik bio., major acquirer — acquired tcg portfolio company carmot therapeutics for $3.3b in december 2023., major acquirer — acquired constellation pharmaceuticals for $1.7b in june 2021., flagship internal program — first crossover fund in tcg ecosystem., major acquirer — acquired exonics therapeutics for up to $1b in june 2019., major acquirer — acquired peloton therapeutics for up to $2.35b in may 2019; also acquired immune design for $0.3b in february 2019., major acquirer — acquired flexus biosciences for $1.3b in april 2015. and major acquirer — acquired aragon pharmaceuticals for up to $1b in august 2013..

  • Nura Biocore portfolio company — led $73.8m series b.Strategic or Co-development Partner · 23 June 2026Nura Bio completed a $73.8M Series B led by The Column Group with participation from Samsara BioCapital, Euclidean Capital, and Sanofi Ventures. The funding advances Nura's SARM1 inhibitor pipeline, including a Phase 1b/2a study of NB-4746 for ALS and a first-in-human study of NB-9402, a next-generation covalent allosteric SARM1 inhibitor. Tim Kutzkey, PhD serves on the board; John Josey, PhD is Chairman of Atavistik Bio and involved with Nura Bio board.
  • Tortugas Neurosciencecore portfolio company — co-led $106m seed and series a.Strategic or Co-development Partner · 21 April 2026Tortugas Neuroscience launched in Framingham, Massachusetts with $106M in combined seed and Series A financing co-led by Cure Ventures, The Column Group, and AN Venture Partners. Funding supports Phase 2 clinical trials for two lead CNS candidates targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. Programs were in-licensed from Eisai Co., Ltd. (Japan) and Jiangsu Hansoh Pharmaceutical Group (China). Led by former Sage Therapeutics executives Jeff Jonas (CEO) and Al Robichaud (R&D head).
  • UCBmajor acquirer — acquired neurona therapeutics for up to $1.15b in april 2026.Strategic or Co-development Partner · 1 April 2026UCB acquired Neurona Therapeutics (a TCG portfolio company developing cell therapies for neuropsychiatric disorders including epilepsy) in April 2026 for up to $1.15 billion, advancing UCB's leadership in epilepsy through regenerative science.
  • Eisai Co., Ltd.strategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from eisai.Strategic or Co-development Partner · 1 April 2026Eisai Co., Ltd. (Japan) licensed clinical-stage CNS drug candidates to Tortugas Neuroscience (TCG portfolio company), targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies.
  • Jiangsu Hansoh Pharmaceutical Groupstrategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from hansoh.Strategic or Co-development Partner · 1 April 2026Jiangsu Hansoh Pharmaceutical Group (China) licensed clinical-stage CNS drug candidates to Tortugas Neuroscience (TCG portfolio company).
  • GSKmajor acquirer — acquired rapt therapeutics for $2.2b in january 2026.Strategic or Co-development Partner · 1 January 2026GSK acquired RAPT Therapeutics (NASDAQ: RAPT), a TCG portfolio company developing oral therapeutics targeting immune drivers of cancer and inflammation, in January 2026 for $2.2 billion.
  • Atavistik Biocore portfolio company — co-led series b.Strategic or Co-development Partner · 18 December 2025Atavistik Bio raised $120M Series B (later extended to $160M total) led by Nextech Invest and The Column Group, with participation from Lux Capital and Regeneron Ventures. The funding advances an oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs). HHT program expected to enter the clinic in H1 2026. Also disclosed a research collaboration with Pfizer to accelerate discovery of novel precision allosteric therapeutics.
  • Nilo Therapeuticscore portfolio company — led series a financing.Strategic or Co-development Partner · 8 October 2025Nilo Therapeutics launched with a $101M Series A led by The Column Group, DCVC Bio, and Lux Capital, with support from the Gates Foundation and Alexandria Venture Investments. The funding supports labs in New York City, R&D expansion, and preclinical programs targeting neural circuits to restore immune homeostasis in autoimmune and inflammatory diseases. Kim Seth was appointed CEO.
  • Swanson Fellowship Program / Robert Swanson legacyflagship talent and ideation program — named after genentech co-founder robert swanson.Others · 1 January 2025The Swanson Fellowship program is a one-year fellowship opportunity for aspiring biotech leaders, focused on new company creation with hands-on mentorship from the TCG team and its iPartners. Named in honor of Robert Swanson, the Co-Founder of Genentech, often considered the father of the biotechnology industry.
  • Incytemajor acquirer — acquired escient pharmaceuticals for $783m in april 2024.Strategic or Co-development Partner · 1 April 2024Incyte acquired Escient Pharmaceuticals (TCG portfolio company advancing first-in-class GPCR-targeted drugs) in April 2024 for $783 million.
  • TCG Labs-Soleil (internal fund)flagship internal program — $400m+ venture-biotech fund integrated with r&d hub.Strategic or Co-development Partner · 1 February 2024TCG Labs-Soleil, launched in February 2024 with over $400M, represents a pioneering venture-biotech model integrating a dedicated venture fund (TCG Labs) with an evergreen R&D hub (Soleil) led by top-tier scientists. Focused on single-asset programs for efficient discovery and development of biologic-based therapies.
  • Pfizerstrategic research collaboration partner with tcg portfolio company atavistik bio.Strategic or Co-development Partner · 1 January 2024Pfizer entered a research collaboration with Atavistik Bio (TCG portfolio company) to accelerate discovery of novel precision allosteric therapeutics for metabolite-protein interactions in metabolic diseases and cancer.
  • Rochemajor acquirer — acquired tcg portfolio company carmot therapeutics for $3.3b in december 2023.Strategic or Co-development Partner · 1 December 2023Roche acquired Carmot Therapeutics (a TCG portfolio company using Chemotype Evolution drug discovery) in December 2023 for $3.3 billion. Separately, Genentech/Roche acquired TCG portfolio company Seragon Pharmaceuticals in August 2014 for $0.8 billion.
  • MorphoSysmajor acquirer — acquired constellation pharmaceuticals for $1.7b in june 2021.Strategic or Co-development Partner · 1 June 2021MorphoSys acquired Constellation Pharmaceuticals (TCG portfolio company pioneering therapeutics targeting epigenetic regulators) on June 2, 2021 for $1.7 billion.
  • TCG Crossover (TCGX)flagship internal program — first crossover fund in tcg ecosystem.Strategic or Co-development Partner · 1 January 2021TCG Crossover (TCGX), launched in 2021, is the first crossover fund debuted under the TCG ecosystem, dedicated to investing in later-stage pre-IPO and public drug discovery companies. Operationally independent of The Column Group (TCG).
  • Vertex Pharmaceuticalsmajor acquirer — acquired exonics therapeutics for up to $1b in june 2019.Strategic or Co-development Partner · 1 June 2019Vertex Pharmaceuticals acquired Exonics Therapeutics (TCG portfolio company developing CRISPR/Cas9 gene editing medicines for Duchenne muscular dystrophy) on June 6, 2019 for up to $1 billion.
  • Merckmajor acquirer — acquired peloton therapeutics for up to $2.35b in may 2019; also acquired immune design for $0.3b in february 2019.Strategic or Co-development Partner · 1 May 2019Merck acquired TCG portfolio company Peloton Therapeutics (first-in-class small-molecule oncology pipeline) in May 2019 for up to $2.35 billion. Merck also previously acquired TCG portfolio company Immune Design (immunotherapy oncology) in February 2019 for $0.3 billion.
  • Bristol-Myers Squibbmajor acquirer — acquired flexus biosciences for $1.3b in april 2015.Strategic or Co-development Partner · 1 April 2015Bristol-Myers Squibb acquired Flexus Biosciences (TCG portfolio company creating cancer therapeutics through immunology insights) in April 2015 for $1.3 billion.
  • Johnson & Johnsonmajor acquirer — acquired aragon pharmaceuticals for up to $1b in august 2013.Strategic or Co-development Partner · 1 August 2013Johnson & Johnson acquired TCG portfolio company Aragon Pharmaceuticals (nuclear receptor targeting drugs for hormone resistant cancers) in August 2013 for up to $1 billion.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

The Column Group competitors and assessment

Company assessment

Direct peers

  • Arch Venture Partners: Arch Venture Partners is a leading biotech-focused venture capital firm that co-invests and competes with TCG for early-stage life sciences opportunities, particularly at company formation. Both firms back scientific founders at top universities and have produced multiple pharma exits (Arch: Illumina, Receptos, Vir).
  • Flagship Pioneering: Flagship Pioneering is a biotech creation engine that both internally generates companies (like Moderna) and partners with academic founders. Highly comparable to TCG's company-formation-led model and its recent TCG Labs-Soleil venture-biotech hybrid approach.
  • Third Rock Ventures: Third Rock Ventures builds biotech companies from academic science with a hands-on operating partner model — directly parallel to TCG's company formation approach. Both firms concentrate on early-stage therapeutic platforms with strong scientific founders.
  • Atlas Venture: Atlas Venture is an early-stage biotech venture firm that builds companies from scratch around academic science — a closely comparable model to TCG Platform funds. Both firms back founders across modalities with focused portfolios.
  • Versant Ventures: Versant Ventures is a healthcare-focused venture firm with comparable company-creation capabilities (e.g., Inception Sciences). Direct competitor for early-stage biotech deals and a natural co-investor or alternative for biotech founders.
  • 5AM Ventures: 5AM Ventures is an early-stage biotech venture firm founded by former TCG-affiliated scientists and focused on company formation. It competes with TCG for academic founders and platform technologies in therapeutics.
  • OrbiMed: OrbiMed is one of the largest dedicated healthcare venture firms investing across stages. It is comparable in biotech focus, multi-stage capital deployment, and is a frequent competitor/co-investor of TCG (Leon Chen previously at OrbiMed).

Broad incumbents

  • Andreessen Horowitz (a16z Bio): a16z's bio/health fund is a broader, larger tech-oriented investor that has expanded into life sciences. It competes for biotech founders and capital but operates a multi-vertical model with technology as its core, unlike TCG's pure-play biotech focus.
  • RA Capital Management: RA Capital is a healthcare-focused crossover and public-market investor (co-invested in Atavistik Bio's Series B extension). Comparable in biotech life-sciences focus but operates a broader crossover/public equity model in addition to private venture.
  • Baker Bros. Advisors: Baker Bros. is a long-only biotech-focused investment firm with significant public and private healthcare exposure. Comparable as a high-conviction biotech specialist and competitor for both private rounds and public crossover deals alongside TCGX.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

The Column Group social profiles

Digital presence

The Column Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Column Group leadership team

Management profile

Number of profiles

Profiles7 records

The Column Group subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

The Column Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Column Group M&A and investment

M&A and investment

M&A

Investments140 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Column Group

What does The Column Group do?

The Column Group is a private venture capital firm dedicated to founding, funding, and growing biotechnology companies across small molecules, biologics, cell therapy, gene therapy, and regenerative medicine. It deploys capital through a coordinated family of funds — TCG Platform, TCG Opportunity, TCG Labs-Soleil, and TCG Crossover (TCGX) — that together support portfolio companies from inception through exit, supplemented by the Swanson Fellowship Program and a deep scientific advisor network.

Is The Column Group a public or private company?

The Column Group is a private company. It is classified as venture growth investor backed and is currently operating.

When was The Column Group founded?

The Column Group was founded in 2007. It employs 11 to 50 people.

Where is The Column Group based?

The Column Group is headquartered in San Francisco, United States, in the North America region.

How does The Column Group make money?

Three revenue lines are on record. Venture capital fund management and carried interest is the primary driver. The others are capital gains from portfolio exits and IPOs and crossover fund investments (TCGX).

Who are The Column Group's main competitors?

Direct peers on record are Arch Venture Partners, Flagship Pioneering, Third Rock Ventures, Atlas Venture, Versant Ventures, 5AM Ventures and OrbiMed. Broad incumbents are Andreessen Horowitz (a16z Bio), RA Capital Management and Baker Bros. Advisors.

Does The Column Group have an API?

No public API is recorded for The Column Group.

What industry is The Column Group in?

The Column Group's product category is Venture Capital (Biotechnology). Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAGAH, Thematic / Sector-Focused Multi-Manager Platforms. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0TriGemX Bio Raises $94 Million To Advance Phase 3 Migraine ProgramTriGemX Bio raised $94 million in financing co-led by The Column Group, TCGX, and Viking Global Investors to advance Phase 3 development of elismetrep, an oral TRPM8 blocker for acute migraine. The company plans to use the proceeds primarily for Phase 3, with first results expected in mid-2027. A new leadership team was also appointed.AlleyWatchThe AlleyWatch Startup Daily Funding Report: 10/2/2026TriGemX Bio raised $94M in venture funding led by The Column Group, TCG Crossover, and Viking Global Investors, bringing its total equity funding to $573M. Walapay raised $4.6M in seed funding led by Generative Ventures for its cross-border payments API.pharmaphorumSpace pharma Varda raises $251m, and other financingsVarda Space Industries closed a $251 million Series D round to fund orbital pharmaceutical manufacturing, led by Lux Capital and Natural Capital. The company claims to be the only one with six successful launches and re-entry missions. Other biotechs also raised funds this week, including Kallyope's $94 million and Breye Therapeutics' €67.5 million.FinSMEsTriGemX Bio Raises $94M in FundingTriGemX Bio raised $94M in funding co-led by The Column Group, TCGX, and Viking Global Investors. The company will use the funds to advance its lead program elismetrep, a Phase 3 oral TRPM8 blocker for acute migraine treatment.BioSpaceTriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for MigraineTriGemX Bio closed a $94 million financing co-led by TCGX and Viking Global Investors to advance elismetrep, a TRPM8 channel blocker for migraine. The company is relaunching with new leadership, and Phase 3 results are anticipated in mid-2027.MarketScreenerCircle Pharma, Inc. announced that it has received $92.5 million in funding from Eli Lilly and Company, Euclidean Capital LLC, RA Capital Management, L.P., The Column Group, LLC, Nextech Invest Ltd.Circle Pharma, Inc. announced a $92.5 million funding round led by The Column Group on September 16, 2026. The round included participation from Eli Lilly, Euclidean Capital, Nextech Invest, and new investor RA Capital Management, with shares issued as convertible preferred shares.BioSpaceCircle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentCircle Pharma announced an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, a first-in-class cyclin D1 inhibitor, into clinical development for ER+ breast cancer in Q1 2027.Business Wire BlogCircle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentCircle Pharma announced an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, a first-in-class cyclin D1 inhibitor, into clinical development for ER+ breast cancer in Q1 2027.FinSMEsCircle Pharma Raises $92.5M in Series E FundingCircle Pharma raised $92.5M in Series E funding led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The company will use the funds to expand operations and R&D on its MXMO platform for cancer therapies.FinSMEsInduPro Raises $77M in Series B FundingInduPro raised $77M in Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, and others. The funds will support Phase 1 clinical development of IDP-001 for advanced non-small cell lung cancer and advance its preclinical pipeline.